News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,944 Results
Type
Article (14898)
Company Profile (299)
Press Release (266741)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79928)
Career Advice (163)
Deals (13359)
Drug Delivery (39)
Drug Development (50706)
Employer Resources (31)
FDA (5844)
Job Trends (5176)
News (145211)
Policy (10083)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (921)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21790)
ALS (125)
Alzheimer's disease (1032)
Antibody-drug conjugate (ADC) (241)
Approvals (6039)
Artificial intelligence (259)
Autoimmune disease (113)
Automation (9)
Bankruptcy (105)
Best Places to Work (4567)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (344)
Cancer (3131)
Cardiovascular disease (237)
Career advice (148)
Career pathing (7)
CAR-T (218)
CDC (5)
Cell therapy (564)
Cervical cancer (14)
Clinical research (43677)
Collaboration (1151)
Company closure (2)
Compensation (596)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (553)
Cystic fibrosis (112)
Data (4325)
Denatured (15)
Depression (92)
Diabetes (255)
Diagnostics (1379)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (188)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (216)
Earnings (31694)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51730)
Executive appointments (623)
FDA (7598)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (982)
Gene editing (182)
Generative AI (21)
Gene therapy (490)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6618)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (40)
Indications (66)
Infectious disease (1205)
Inflammatory bowel disease (156)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7361)
IRA (12)
Job creations (869)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1403)
Liver cancer (41)
Longevity (11)
Lung cancer (420)
Lymphoma (249)
Machine learning (24)
Management (7)
Manufacturing (376)
MASH (130)
Medical device (2666)
Medtech (2675)
Mergers & acquisitions (6622)
Metabolic disorders (725)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (231)
Neuropsychiatric disorders (70)
Neuroscience (1954)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (330)
Peanut (43)
People (26671)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15477)
Phase 2 (20292)
Phase 3 (12825)
Pipeline (3264)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (146)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (651)
Real estate (1451)
Recruiting (12)
Regulatory (9908)
Reports (19)
Research institute (972)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (183)
Series B (136)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (334)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (52)
Last 7 days (326)
Last 30 days (1165)
Last 365 days (17848)
2026 (1702)
2025 (18100)
2024 (20551)
2023 (22419)
2022 (26825)
2021 (27809)
2020 (23366)
2019 (16248)
2018 (11762)
2017 (13755)
2016 (11859)
2015 (14366)
2014 (10400)
2013 (7517)
2012 (7582)
2011 (7668)
2010 (7457)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18257)
Australia (3111)
California (7079)
Canada (1839)
China (774)
Colorado (247)
Connecticut (252)
Delaware (235)
Europe (39177)
Florida (903)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (161)
Iowa (8)
Japan (224)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5588)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1648)
New Mexico (13)
New York (1763)
North Carolina (827)
North Dakota (6)
Northern California (3477)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1280)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2808)
Tennessee (40)
Texas (911)
United States (23355)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,944 Results for "vividion therapeutics inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vividion Publishes Discovery of WRN Inhibitor VVD-214 in Journal of Medicinal Chemistry
January 6, 2026
·
3 min read
Press Releases
Vividion Publishes Discovery of First-in-Class KEAP1 Activator, Supporting Ongoing Clinical Program in Oncology
December 23, 2025
·
3 min read
Press Releases
Vividion Therapeutics Appoints Sam Whiting, M.D., Ph.D., as Chief Medical Officer
August 14, 2025
·
3 min read
Press Releases
Vividion Announces Publication in Science of Preclinical Data on Covalent Inhibitors of RAS-PI3K that Block Tumor Growth
October 9, 2025
·
4 min read
Press Releases
Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor
June 4, 2025
·
6 min read
Biotech Beach
Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)
Vividion Therapeutics, Inc. today announced a landmark publication in Nature.
April 25, 2024
·
4 min read
Press Releases
Vividion Therapeutics Announces Promotion of Jean Bemis to Chief Operating Officer
January 22, 2025
·
3 min read
Press Releases
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
April 3, 2025
·
5 min read
Press Releases
Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform
January 8, 2025
·
6 min read
Bio NC
Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics Agreement includes the discovery and enhancement of targeted oncology drug targets and biomarkers, in addition to positioning existing compounds
Tavros Therapeutics, Inc., a precision oncology platform company, announced that the Company has achieved two milestone payments in its collaboration with Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG.
May 14, 2024
·
3 min read
1 of 28,195
Next
